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AtherosclerosisTobacco smoking is the major cause of preventable death
worldwide, resulting in almost 6 million deaths per year. Up to 10
per cent of all deaths are accredited to cardiovascular diseases
(CVD), with the prevalence of fatal CVD events being highest among
young adults below the age of 45. In fact, fatal CVD events are the
leading cause of premature deaths in young smokers [1]. This
suggests that smoking rapidly leads to modiﬁcations within the
cardiovascular system with potentially pathological consequences.
In line with this observation, several studies have demonstrated
tobacco-smoke induced alterations, like increased aortic and ca-
rotid intima media thickness (a- and c-IMT) and endothelial
dysfunction e all key features of CVD e in healthy and young
passive smokers [2e5].
Epidemiological studies suggest that atherosclerosis, the un-
derlying cause of most CVDs, is initiated with a diffuse intimal
thickening by accumulating extracellular matrix (ECM)-containing
proteoglycans like biglycan (BGN) or decorin [6]. In this issue of
Atherosclerosis, Mandrafﬁno and colleagues analysed a large
number (n > 250) of healthy young current smokers and found
increased monocytic BGN expression, which highly correlated with
arterial stiffness and c-IMT [7]. Their ﬁndings are of special rele-
vance regarding CVDs as they provide strong evidence for the early
onset and accelerated atherogenesis in young cigarette smokers.DOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.024.
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nd/3.0/).According to the “response-to-retention hypothesis”, athero-
sclerosis develops as a consequence of cumulating lipoproteins in
the arterial wall [8]. Actually, all proteoglycans are able to bind li-
poproteins due to ionic interactions in vitro, however Apolipopro-
tein B, the major lipoprotein of atherogenic LDLs, was found in
human lesions to preferentially co-localize with BGN. In line with
this observation, mounting evidence supports BGN as a major
player in the initiation and development of atherosclerosis. For
example, overexpression of human BGN in LDLR/ mice resulted
in increased lesions [9], while mice expressing proteoglycan-
binding-defective apoB demonstrated lower degree of atheroscle-
rosis [10].
Whether smoking increases the BGN concentration in the ECM
of the artery wall, initiating atherosclerosis as proposed in the
“response-of-retention hypothesis”, still needs deﬁnite proof, but at
least seems plausible. For instance, BGN expression is induced by
transforming growth factor beta-1 (TGFb), which is linked to the
occurrence and severity of CVD, and found to be increased in the
small airway epithelium of tobacco smokers [11]. Furthermore,
increased oxidative stress and hypertension, both consequences of
heavy smoking, have been demonstrated to promote BGN expres-
sion [12,13]. However, in-vitro studies, i.e. smoke-extract treatment
of smooth muscle and/or endothelial cells, might shed more light
into the causal link between smoking, increased intimal BGN
expression and atherogenesis.
Increased monocytic BGN expression and release could also
potentially accelerate atherosclerosis. Additionally to the secretion
of BGN, monocytes/macrophage-derived matrix metallo-proteases,
i.e. MMP-2, MMP-3 and MMP13, proteolytically cleave BGN from
ECM and increase BGN concentrations in the blood [14]. In this
context, soluble BGN has been identiﬁed as an endogenous danger
signal capable of inducing the sterile inﬂammation response of
macrophages and dentritic cells via simultaneous stimulation of
TLR2/4 and P2X7/P2X4 receptors [15]. Consequently, activated
immune cells secrete mediators like TNF and IL-1 beta, resulting in
the pro-inﬂammatory state that can also be observed in smokers.
Large scale studies, like that presented by Mandrafﬁno and
colleagues, are highly valuable for the identiﬁcation of smoking
induced alterations, which can have large variations due to several
different factors. Cigarette smoke contains more than 4500
different chemical compounds, oxidants, and metals, and theirarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
R. Baumgartner / Atherosclerosis 237 (2014) 809e810810concentrations may vary due to tobacco breed and additives.
Further, smoking behaviour, including inhalation intensity and
duration, could inﬂuence the results. Indeed, existing data indicates
that smoking is an enormous health risk for both the active and
passive smokers. Passive smoking or moderate smoking has been
shown to rapidly lead to changes in blood markers, which are
linked with development of different pathologies [16]. Some of the
noxious effects triggered by smoking may return to baseline after
smoking cessation, but others are non-reversible or may need de-
cades to become negligible, resulting for example in an elevated
risk for developing CVDs also for smoking quitters [17].
Smoking is a critical contributor for the initiation and acceler-
ation of atherosclerosis and CVDmortality. Despite the fact that the
smoking-related mechanisms of action are not yet fully under-
stood, the report by Mandrafﬁno et al. reveals substantial insights
towards a better understating of its causal relation. This may ﬁnally
lead to measures of early detection of smoke induced pathologies,
when treatment has the highest probability of success.References
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